JMP Securities Maintains Market Outperform on CRISPR Therapeutics, Raises Price Target to $74
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan maintains a Market Outperform rating on CRISPR Therapeutics (NASDAQ:CRSP) and raises the price target from $70 to $74.
June 09, 2023 | 3:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities maintains a Market Outperform rating on CRISPR Therapeutics and raises the price target from $70 to $74.
The news of JMP Securities maintaining a Market Outperform rating and raising the price target for CRISPR Therapeutics (CRSP) from $70 to $74 is positive for the stock. This indicates that the analyst has a bullish outlook on the company's performance and expects the stock price to rise in the short term. As a result, this news is likely to have a positive impact on CRSP's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100